Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi70-vi73; doi:10.1093/annonc/mdm229
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lorusso, V
Right arrow Articles by Silvestris, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorusso, V
Right arrow Articles by Silvestris, N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast and ovarian cancer

Role of liposomal anthracyclines in breast cancer

V Lorusso1,*, L Manzione2 and N Silvestris3

1 Medical Oncology Unit, Vito Fazzi Hospital, Lecce
2 Medical Oncology Unit, San Carlo Hospital, Potenza
3 Medical Oncology Unit, SS Annunziata Hospital, Taranto, Italy

* Correspondence to: Dr V. Lorusso, Medical Oncology Unit, AUSL LE, Vito Fazzi Hospital, Piazza Muratore, 73100 Lecce, Italy. Tel: +39-0832-661962; Fax: +39-0832-661962; E-mail: vitolorusso{at}inwind.it

Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.

Key words: breast cancer, cardiotoxicity, liposomal anthracyclines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.